Clinical trials: Septicaemia
Sepsis, Septic Shock
NAI for Sepsis With Persistent Lymphopenia
This is a Phase 2, randomized, open-label study evaluating the safety and efficacy of nogapendekin alfa inbakicept (NAI, ANKTIVA®) in combination with standard of care versus standard of care alone in critically ill adults with…
- Conditions
- Sepsis, Septic Shock, Lymphopenia, Immunosuppression
- Trial name
- NCT07578558
- Testing
- Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC)
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
Sepsis, Sepsis Bacterial
Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.
Abionic has developed a targeted, rapid test for pancreatic stone protein (PSP) in human K2-EDTA venous whole blood using the abioSCOPE instrument.
- Trial name
- NCT05627076
- Testing
- Blood Sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Abionic SA
Severe Sepsis
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05060250
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Bluejay Diagnostics, Inc.
Catecholamine-resistant Hypotension (CRH), Distributive Shock
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Trial name
- ATHOS-3 (NCT02338843)
- Testing
- LJPC-501
- Where
- 115 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- La Jolla Pharmaceutical Company
VAP - Ventilator Associated Pneumonia
LUNG INFECTION IN ICU (LUNG-I3)
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
- Trial name
- LUNG-I3 (NCT06073834)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- BioMérieux
Monitoring, Physiologic, Vital Signs
Bodytrak® Feasibility Study
Bodytrak® is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone…
- Conditions
- Monitoring, Physiologic, Vital Signs, Sepsis, Altered Level of Consciousness
- Trial name
- NCT03139955
- Testing
- Bodytrak
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Inova Design Solutions Ltd
Hypertension
Antihypertensive Medications and the Risk of Sepsis
The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with the other major antihypertensive classes, including ACEIs…
- Trial name
- NCT02248896
- Testing
- Telmisartan, Other angiotensin-receptor blockers (ARBs), Angiotensin-converting enzyme inhibitors (ACEIs)
- Volunteers
- 1,129,062 people
- Sponsor
- Boehringer Ingelheim
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Hypotension
Efficacy Study of a Facemask Device to Treat Hypotension
The purpose of this study is to determine if the impedance threshold device (ITD) attached to a facemask can increase blood pressure in patients who present to the emergency department with hypotension secondary to hypovolemia.
- Trial name
- NCT00256724
- Testing
- Impedance Threshold Device
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Advanced Circulatory Systems
Sepsis, Severe Sepsis
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis.
- Conditions
- Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome, Sepsis Syndrome
- Trial name
- NCT00448968
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Inverness Medical Innovations
Sepsis, Infection
CV-SQuISH-ED: Clinical Validation Study
This is a study to evaluate the diagnostic performance of the investigational Cytovale System \& IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to the emergency department with signs or…
- Trial name
- NCT04933760
- Testing
- Cytovale IntellipSep test
- Where
- 4 sites in United States
- Volunteers
- 599 people
- Sponsor
- Cytovale, Inc.
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Cure Rate
A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
- Trial name
- NCT01860989
- Testing
- KAE609
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals